<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is a well characterized entity </plain></SENT>
<SENT sid="1" pm="."><plain>For atypical findings a term Burkitt-like <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (B-LL) was applied in the past, but the interpretation of the morphological appearances was subjective and poorly reproducible </plain></SENT>
<SENT sid="2" pm="."><plain>We used a combined approach (<z:mp ids='MP_0000002'>morphology</z:mp> using classical histological staining; immunohistochemistry-IHC; fluorescence in situ hybridization-FISH on interphase nuclei; cytogenetics) to perform a retrospective study on 39 patients diagnosed as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and B-LL at our department in the years 1982 to 2002 </plain></SENT>
<SENT sid="3" pm="."><plain>By FISH we demonstrated t(8;14)(q24;q32) in 31 patients; in further two we found a break at 8q24, suggestive of a variant translocation </plain></SENT>
<SENT sid="4" pm="."><plain>In three patients with the cytogenetic investigation available we confirmed the findings of FISH--two <z:hpo ids='HP_0002665'>lymphomas</z:hpo> had the t(8;14)(q24;q32), one had t(2;8)(p12;q24) </plain></SENT>
<SENT sid="5" pm="."><plain>IHC showed CD20, CD10, BCL-6, p53 expression, and Ki-67 antigen in &gt; 95% of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell population in a majority of the patients </plain></SENT>
<SENT sid="6" pm="."><plain>There was a group of 4 patients in whom the t(8;14)(q24;q32) or a break at 8q24 were not found (FISH) </plain></SENT>
<SENT sid="7" pm="."><plain>These cases were reclassified within the WHO defined grey zone subgroup of B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> unclassifiable with features intermediate between diffuse large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>--I-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Two further cases were reclassified as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> based on a combined IHC and FISH findings </plain></SENT>
<SENT sid="9" pm="."><plain>A <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of one of these patients had breaks at 3q27 (BCL6) and at 14q32 (IGH) suggestive of t(3;14)(q27;q32) </plain></SENT>
<SENT sid="10" pm="."><plain>The overall survival estimate of 33 patients with the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> was 54% </plain></SENT>
<SENT sid="11" pm="."><plain>Most of <z:hpo ids='HP_0011420'>deaths</z:hpo> occurred within 6 months after the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> diagnosis </plain></SENT>
<SENT sid="12" pm="."><plain>The unfavorable clinical outcome appears to be associated with a strong expression of the p53 protein in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell population </plain></SENT>
<SENT sid="13" pm="."><plain>Individually utilized methods in the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> may lead to false diagnostic conclusions </plain></SENT>
<SENT sid="14" pm="."><plain>A combined approach helps to establish a more reliable diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and to separate grey zone <z:hpo ids='HP_0002665'>lymphomas</z:hpo> I-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> with morphological mimics of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> to start adequate treatment </plain></SENT>
<SENT sid="15" pm="."><plain>I-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> is a non-homogenous group of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> necessitating further analysis in a prospective study </plain></SENT>
</text></document>